Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ: AXSM )

121.69 +2.24 (+1.88%)
Streaming Delayed Price Updated: 3:50 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Why Axsome Therapeutics Stock Is Rising Today
Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares are trading higher Wednesday following a recent corporate presentation. 
Via Benzinga
Axsome Therapeutics Expects Up To $11.5 Billion In Peak Sales, Wallops Analysts' Forecasts
The company's biggest products treats depression and could be used in other conditions. 
Via Investor's Business Daily
Analyst Expectations for Axsome Therapeutics's Future
Via Benzinga
3 No-Brainer Stocks to Buy in June
These biopharma stocks could be big winners. 
Via The Motley Fool
The Top Healthcare Stocks to Buy With $100
You don't need a fortune to start investing. 
Via The Motley Fool
Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023
Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apnea 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics's Return On Capital Employed Overview
Via Benzinga
3 Growth Stocks to Buy and Hold
These three stocks defied the bear market last year. 
Via The Motley Fool
Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Prediction: These 2 Stocks Could Double In the Next Year
It would be a continuation of solid recent performances. 
Via The Motley Fool
2 Biotech Stocks That Could Help Set You Up for Life
These two promising companies have the potential to beat the market over time. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Bear Market Defying Stocks to Buy in May
These stocks still have plenty of market-beating years ahead. 
Via The Motley Fool
Expert Ratings for Axsome Therapeutics
Via Benzinga
Earnings Outlook For Axsome Therapeutics
Via Benzinga
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
Both Axsome Therapeutics and Exelixis have potentially game-changing products in their pipelines. 
Via The Motley Fool
Is a Victory for Its Rivals Bad News for Axsome Therapeutics?
The biopharmaceutical company's shares have soared during the past year. 
Via The Motley Fool
Market Rally Diverges; Google Surges On AI News, Inflation Cools, But Breadth Weak: Weekly Review
The Nasdaq hit a new 2023 high, but not the S&P 500 or Dow Jones. 
Via Investor's Business Daily
This Analyst Creates Bullish Pitch For Axsome Therapeutics On Increased Outlook For Its Depression Drug
Mizuho increased the price target on Axsome Therapeutics Inc (NASDAQ: AXSM) from $84 to $95 with a Buy rating 
Via Benzinga
2 Magnificent Growth Stocks You Can Buy With $150 Right Now
You don't have to wait until you're rich to start getting your money to work for you. 
Via The Motley Fool
Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?
The biotech's share price more than doubled during last year's bear market. 
Via The Motley Fool
Axsome Therapeutics Clocks Better Than Expected Q1 Sales, Depression Drug Sees Improved Coverage
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q1 revenue of $94.6 million, consisting of net product sales of $28.6 million, license revenue of $65.7 million, and  
Via Benzinga
Axsome Therapeutics (AXSM) Q1 2023 Earnings Call Transcript
AXSM earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Axsome Surges As Its Newest Product Shines. But BioXcel Does The Opposite.
Axsome shares are nearing a breakout point. But BioXcel crumbled on its report. 
Via Investor's Business Daily
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month
One World Trade Center to be lit up in green in observance of Mental Health Month 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy
Here are three biotech stocks with promising innovations that could provide catalysts for their respective stocks in 2023 
Via InvestorPlace
NASDAQ: AXSM Shareholder Notice: Investigation over Potential Wrongdoing at Axsome Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 04/27/2023 -- Certain directors of Axsome Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
3 Biotech Stocks to Watch After Johnson & Johnson’s Earnings Beat
Discover the latest picks in the biotech industry with our article on 3 biotech stocks to watch after Johnson & Johnson’s earnings beat. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.